AbbVie Submits Regulatory Application to FDA for Risankizumab-Rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn’s Disease

AbbVie announced that it has submitted an application to the US FDA seeking approval for risankizumab-rzaa, an interleukin-23 inhibitor, for the treatment of patients 16 years and older with moderate to severe Crohn’s disease.